An Open-Label Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Avonex (Interferon Beta-1a) in Chinese Subjects With Relapsing Multiple Sclerosis.
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 03 Nov 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
- 03 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.